When will the U.S. develop concise generic biologic rules?

A lot of people have been asking my opinion on when a concise generic biologic regulatory pathway will emerge in the United States, and I give them all the same answer: Later.
In my opinion complex regulatory schemes are not areas in which the United States can effectively lead. Why not? Because the size of the [...]

Commercializing biotechnology in China

I recently had the opportunity to conduct a brief interview with Mireille Gingras, Ph.D. President and CEO of HUYA Bioscience on doing business with and in China:
Tell me about HUYA and what makes the company unique?
HUYA Bioscience International has pioneered the most innovative and productive approach for pharmaceutical co-development between the U.S. and China. [...]

Drug Patent Expirations in September 2008

Courtesy of DrugPatentWatch.com:
Drug Patent Expirations in September 2008
*Drugs may be covered by multiple patents

Tradename
Applicant
Generic Name
Patent Number
Patent Expiration

ANDRODERM
Watson Labs
testosterone
4,855,294
Sep 6, 2008

AVITA
Mylan Bertek
tretinoin
5,045,317
Sep 3, 2008

DDAVP
Sanofi Aventis Us
desmopressin acetate
5,047,398
Sep 10, 2008

OPANA ER
Endo Pharms
oxymorphone hydrochloride
5,128,143
Sep 19, 2008

RESCULA
R Tech Ueno Ltd
unoprostone isopropyl
5,001,153
Sep 19, 2008

Courtesy of DrugPatentWatch.com